RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
Abstract
Cancer drugs often lose their effectiveness because tumors acquire genetic changes that confer drug resistance. Ideally, patients would be switched to a different drug before tumor growth resumes, but this requires early knowledge of how resistance arose. Miyamoto et al. have developed a non-invasive method to spot resistance by sequencing RNA transcripts in single circulating tumor cells (CTCs) (see the Perspective by Nanus and Giannakakou). For example, in prostate cancer patients, drug resistance was triggered by activation of the Wnt signaling pathway. But CTCs are rare and fragile, and the technology needs further development before it is used in clinical practice.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 18, 2015
- Source ID
- 10.1126/science.aab0917
Entities
People
- Ben S. Wittner
- Brian W. Brannigan
- Chin-lee Wu
- Daniel Haber
- David T Ting
- David T. Miyamoto
- Douglas B. Fox
- Douglas M. Dahl
- Huili Zhu
- Julie Trautwein
- Katherine T. Broderick
- Kshitij S. Arora
- Lecia V. Sequist
- Matthew R Smith
- Mehmet Toner
- Niyati Desai
- Ravi Kapur
- Richard J. Lee
- Rushil Desai
- Shyamala Maheswaran
- Sridhar Ramaswamy
- Toshi Shioda
- Yu Zheng
Organizations
- Affymetrix
- Burroughs Wellcome Fund
- Harvard Medical School
- Howard Hughes Medical Institute
- Johnson & Johnson
- Massachusetts General Hospital
- National Cancer Institute
- National Institute of Biomedical Imaging and Bioengineering
- National Institutes of Health
- Prostate Cancer Foundation
- Stand Up to Cancer
- United States Department of Defense